Readcivir clinical trial officially launched in Wuhan: 761 patients

category:Internet
 Readcivir clinical trial officially launched in Wuhan: 761 patients


On the same day, a reporter from www.thepaper.cn also learned from Gilead science that Gilead has reached an agreement with Chinas health sector to support two clinical trials for 2019-ncov infected people to determine the safety and effectiveness of ridcivir as a potential treatment for coronavirus. Gilead provides free drugs for the research and supports the design and development of the research.

One of the studies evaluated the efficacy of ridcivir in patients who were hospitalized with 2019 ncov but did not show significant clinical symptoms (e.g., need additional oxygen), while the other evaluated the efficacy of ridcivir in patients with more severe clinical symptoms (e.g., need oxygen). The two clinical trials, led by Chinese researchers, were conducted in Wuhan. According to the Sino Japanese Friendship Hospital, 761 patients will be enrolled in the above clinical trials, including 308 patients with mild and moderate diseases and 453 patients with severe diseases. Cao Bin, a professor at China Japan Friendship Hospital, said the study will carry out a strict randomized double-blind trial to evaluate the efficacy and safety of ridcivir in patients with new coronavirus pneumonia. Radcivir is a kind of drug which has been used in the treatment of Ebola virus infection in foreign countries. However, it has shown good in vitro activity in the process of virus screening in domestic research institutions. Previously, the State Food and drug administration has agreed that China Japan Friendship Hospital and the Chinese Academy of medical sciences can carry out clinical trials in patients infected with the new coronavirus. Source: surging news editor: Wang Fengzhi, nt2541

One of the studies evaluated the efficacy of ridcivir in patients who were hospitalized with 2019 ncov but did not show significant clinical symptoms (e.g., need additional oxygen), while the other evaluated the efficacy of ridcivir in patients with more severe clinical symptoms (e.g., need oxygen). The two clinical trials, led by Chinese researchers, were conducted in Wuhan.

According to the Sino Japanese Friendship Hospital, 761 patients will be enrolled in the above clinical trials, including 308 patients with mild and moderate diseases and 453 patients with severe diseases. Cao Bin, a professor at China Japan Friendship Hospital, said the study will carry out a strict randomized double-blind trial to evaluate the efficacy and safety of ridcivir in patients with new coronavirus pneumonia.

Radcivir is a kind of drug which has been used in the treatment of Ebola virus infection in foreign countries. However, it has shown good in vitro activity in the process of virus screening in domestic research institutions. Previously, the State Food and drug administration has agreed that China Japan Friendship Hospital and the Chinese Academy of medical sciences can carry out clinical trials in patients infected with the new coronavirus.